• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

BridgeBio gears up for FDA review of acoramidis following Phase III results

cafead

Administrator
Staff member
  • cafead   Jan 11, 2024 at 11:12: AM
via BridgeBio submitted the NDA with US FDA for the TTR stabiliser in December 2023 and plans to engage with other regulatory bodies this year.

article source
 

<